Topic: Thomson Reuters Corporation
LOS ANGELES (Reuters) - The Medicare federal health insurance program has proposed removing its requirement that kidney dialysis providers keep patient hemoglobin levels above a set minimum, which could lead to lower use of Epogen, the anemia drug sold by Amgen.The government ...
LOS ANGELES (Reuters) - Medicare officials do not plan at this time to change payment terms for anemia drugs used in kidney patients who are undergoing dialysis.The agency, which is slated to issue a final decision on the matter in June, also ...
